Login to Your Account



Clinic Roundup


Tuesday, July 26, 2011
Threshold Pharmaceuticals Inc., of Redwood City, Calif., initiated a clinical trial of TH-302 in combination with bevacizumab (Avastin, Roche AG) in patients with recurrent high-grade astrocytoma including glioblastoma. TH-302 is a novel small-molecule hypoxia-targeted prodrug that is selectively activated by the low oxygen conditions believed to be induced in tumors by antiangiogenic therapies such as bevacizumab.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription